Linked Life Data

16702831

Source:http://linkedlifedata.com/resource/pubmed/id/16702831

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2006-5-16
pubmed:abstractText
Degeneration of axons and their cell bodies is thought to occur progressively from the onset of multiple sclerosis and to be a significant cause of increasing disability. The mechanisms of neurodegeneration are becoming clearer and this work has already indicated potential molecular targets for therapeutic intervention to prevent neuronal injury. Attention is being directed at the appropriate design of clinical trials to test neuroprotection as a major strategy for the management of multiple sclerosis. The subtype of multiple sclerosis, the primary outcome measure and other detailed design issues remain controversial. This review considers the rationale for different therapeutic strategies for neuroprotection and discusses the controversies of trial design.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1350-7540
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
255-9
pubmed:dateRevised
2011-11-4
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Neuroprotection in multiple sclerosis: therapeutic strategies and clinical trial design.
pubmed:affiliation
National Hospital for Neurology and Neurosurgery, Queen Square, London, UK. r.kapoor@ion.ucl.ac.uk
pubmed:publicationType
Journal Article, Review